Abstract
Background: Tuberculosis has been a major cause of suffering and death since times immemorial, thought to be one of the oldest human diseases. Drug resistance is a threat to TB control programs worldwide. Patients infected with multiple-drug resistant strains are less likely to become cured. Therefore we planned this study to analyze the various socioeconomic correlates influencing development of drug resistance among MDR-TB patients
Objective:
1. To assess socio economic distribution of MDR cases reported at hospital
2. To find out various socio demographic correlates of MDR cases reported at hospital.
Method:It was a hospital based observational study. Informed consent of the patient was taken for the study. Approval from institutional ethical committee was obtained for the thesis. All information to accomplish objectives was collected by personal interview of each of the study subjects for about 30 to 45 minutes at PMDT site using pre-designed and pre-tested Proforma.
Results: There was a peak of admission of the patients in July month (n=60, 20.83%).Most of the patients (95.48%) belong to three districts namely Ajmer, Nagour and Bhilwara.MDR TB can affect all the age groups. In the study population, 214 (74.30%) patients were in the reproductive and economically productive age group of 16-45 years. One hundred and sixty patients (55.55%) had history of addiction and it was observed significant association of MDR TB with addiction habit.
Keywords: MDR cases; socio demographic correlates.
References
1. Rosenblatt MB. Pulmonary tuberculosis: evaluation of modern therapy. Bull NY Acad Med 1973; 49:163-96.
2. World Health Organization. Global tuberculosis control: WHO report 2012.WHO/HTM/TB/2012.6. Geneva, Switzerland; WHO 2012.http://www.who.int/tb.
3. Anonymous. Tuberculosis: a global emergency. World Health Forum 1993; 14:438.
4. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367 : 938-40.
5. Corbett EL, Watt CJ, Walker N, Maher D, Williams B, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemics. Arch Intern Med 2003; 163: 1009-21.
6. World Health Organization. Anti-tuberculosis drug resistance in the world; Report no. 4; WHO/HTM/TB/2008.394. Geneva, Switzerland: http://whqlibdoc.who.int/hq/2008.394.eng.pdf, accessed on April 5, 2010.
7. Multidrug resistant tuberculosis. ICMR. 1999; 29 (10 and 11):105-14.
8. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, HorsburghJr CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-32.
9. Mahmoud AMD, Michael D, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. AMA 1993; 270:65-8.
10. Pant R, Pandey KR, Joshi M, Sharma S, Pandey T, Pandey S: Risk Factor Assessment of Multidrug-Resistant Tuberculosis: J Nepal Health Res Counc 2009 Oct;7(15):89-92.
11. Bhatt G, Vyas S, Trivedi K. An epidemiological study of multidrug resistant tuberculosis cases registered under RNTCP of Ahmadabad city. Indian J Tuberc 2012; 59: 18-27.
12. Fleming MF, Krupistky E, Tsoy M, Zvartau E, Brazhenko N, Jakubowiak W, McCaul ME. Alcohol and drug use disorders, HIV status and Drug resistance in a sample of Russian TB patients. Int J Tuberc Lung Dis 2006 May; 10(5):565-70.
13. Ruddy M, Balabanova Y, Graham C et al. Rates of drug resistance and risk factors analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax. 2005 Feb; 60(2):130-5.
14. Barroso E C, SalaniMota R M, Oliveira Santos R O, Oliveira Sousa A L, BrasileiroBarroso J, Nobre Rodrigues J L. Risk factors for acquired multidrug-resistant tuberculosis. J Pneumol 2003; 29: 89–97.
15. Marahatta SB, Kaewkungwal J, Ramasoota P, Singhasivanon P. Risk factors of multidrug resistant tuberculosis in central Nepal: a pilot study. Kathmandu Univ Med J (KUMJ). 2010 Oct-Dec; 8(32):392-7.)
Corresponding Author
Dr Neeraj Gour
Flat No G-1, Sai Villa Apartment, Rajni Gandha Colony,
Gole Ka Mandir, Gwalior (M.P.) India
Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Mobile: 07837585818, 08199997935